National Medicine War Northeast
Release time: 2010-04-30 & nbsp & nbsp & nbsp Source:
Capital advantage，Chinese Medicine Group again，Dalian Meiluo Pharmaceutical (600297,SH) wholesale and retail chain assets under the return of His Majesty。
April 24，Mero Pharmaceutical announced，Injecting subordinates' commercial circulation assets and business into Chinese Medicine Holdings Mero (Dalian) Co., Ltd.，Sinopharm Holdings (1099.HK) subsidiaries will have equity cooperation with Sinopharm Holdings Mero and Dalian Meiro Dali Pharmacy Chain Co., Ltd.。
April 26，A person from the Sinopharm Group told reporters，Chinese Medicine Holdings will hold the joint venture，"Acquisition Mero Pharmaceutical Commercial Assets，It is intended to expand the network and sales。”
But the person close to Meiluo Pharmaceutical revealed，"The two parties have been talking for a long time，Sinopharm Group not only wants to acquire Mero Pharmaceutical's commercial assets，More interested in the entire Mero Pharmaceutical。”
Meiluo Pharmaceutical is the main pharmaceutical company in the Northeast，If you get Mero Pharmaceutical，This will enrich the pharmaceutical industry strength of the Chinese Medicine Group，So as to have a bone piece of injury department、Fish ichthyosis tablets、Pearl Po An Shen Dan and other national traditional Chinese medicine protection varieties。
stake sports betting stake online sports bettingappThis newspaper has not been confirmed by the two parties.
stake sports betting appMero Pharmaceutical Announcement Declaration，Mero Pharmaceutical will include the subsidiary Dalian Meiluo Pharmaceutical Company、Dalian Meiro Co., Ltd. New Pharmaceutical Company、Dalian Meiro Pharmaceutical Supply Company、Commercial circulation assets and business, including Dalian Meiruo Chemical Reagent Company, transferred to the wholly -owned subsidiary Sinopharm Holdings Mero (Dalian) Co., Ltd. (referred to as "National Control Mero")
Data display，As of March 31, 2010，Mero Pharmaceutical's transfer of assets transferred assets for total 180 million yuan，Among them, the account receivable is 153 million yuan，Liabilities totaling 142.12 million yuan，Net assets are RMB 38005 million。With the consent of both parties，The total price of the transfer of assets is 380.55 million yuan。
After the asset injection is completed，Meiluo Pharmaceutical will be based on national control Mero，Introduction of domestic pharmaceutical business giants Chinese medicine holding。"Sinopharm Holdings or its designated subsidiaries conduct equity cooperation on the subsidiary Sinopharm Holding Mero Corporation and Dalian Meiro Dali Pharmacy Chain Co., Ltd.。”
It is reported，National Control Mero is a new company set up for this acquisition。
Mero Pharmaceutical did not disclose the acquisition of Chinese medicine holding this time，Is it a wholly -owned acquisition or just hold it。People close to Meiluo Pharmaceutical said，"National Control won the business business of Mero Pharmaceutical this time，The layout of Dalian is also realized。Although the Chinese Medicine Holdings has the national control Shenyang distribution center in the Northeast，But in Dalian，Sinopharm Holdings No cloth。”
The main pharmaceutical assets of Mero Pharmaceuticals are divided into the Industrial Division and the Business Division，People who are close to Mero said，"Mero Pharmaceutical is the main local commercial company in Dalian，annual sales at more than 1 billion yuan。”
For the sale of My stake betting appcommercial assets，Mero Pharmaceutical said，To expand the market share，The need for market competition in the new environment，Being equal and mutually beneficial、Principles of complementary advantages，It is for a long time、Comprehensive strategic partnership，Realize resource sharing、Common development，Meiro and Sinopharm Holdings cooperate with hand。
Back to the Chinese Medicine Holdings，Mero Pharmaceutical hopes to use the Chinese medicine control to control the distribution network of more than 20 provinces and cities across the country，Selling the company's products to the whole country。Agreement in the agreement signed by both parties，42 varieties produced by the pharmaceutical factory of Mero Pharmaceuticals entering the national drug catalog，In the future, the two parties shall be shared by the two parties，Determine about 10 varieties in the directory，Sales of Sinopharm Holdings in its system。
Chinese medicine person said，After winning Mero Pharmaceutical Business，"National Control Shenyang should be integrated with Chinese medicine holding Mero"。
or "one pot" Meiluo Pharmaceutical
But this time the acquisition of Mero Pharmaceutical's commercial assets is not the ultimate purpose of the Sinopharm Group，and its ultimate purpose is to acquire the entire Mero Pharmacy。
The above -mentioned person close to Meiluo Pharmaceutical，"Before the mergers and acquisitions settled，Sinopharm Holdings has always had two versions of the acquisition of Mero Pharmaceutical: one plan is that the Sinopharm Group ‘one pot” all acquires Mero Pharmaceutical; the other plan is to acquire Mero Pharmaceutical business assets。”
"Sinopharm Group really wants to buy Meiro Pharmaceutical this time，And the two parties have been in contact for a long time。"The person said。
2009 financial report display，Mero Pharmaceutical's operating income of 1.337 billion yuan，5.75 % from the previous year; net profit of 1408 million yuan，but a decrease of 64.62 % over the previous year。The decline in net profit is mainly due to stake online sports bettingthe stake online sports bettingcompany's subordinates of the Mero Pharmaceutical Factory and the Mero Chinese Pharmaceutical Factory.。
It is not surprising to acquire Mero Pharmaceuticals to the Chinese Medicine Group，April 23，Sinopharm Group just signed a contract with Shanxi Weichida Company，Chinese Medicine Group Holdings Shanxi Weichida。
Facts，After successful listing，Sinopharm Group with sufficient cash，M & A target is not limited to the business field，and also point the M & A spear head to the pharmaceutical leading enterprise in various regions。
An analyst of a pharmaceutical industry said，After the Chinese Medicine Holdings is listed，The National Medicine Group plans to get 6 billion yuan this year for mergers and acquisitions，Chinese medicine is not just to become the largest business enterprise in China，Also want to be the most influential comprehensive pharmaceutical company。
Meiluo Pharmaceutical is an important pharmaceutical manufacturer in Liaoning，It is the initiator by Mero Group，Substantially launched on July 30, 1999。Listed on the Shanghai Stock Exchange on November 16, 2000。
Meiluo Pharmaceutical now owns the Meiro Pharmaceutical Factory、Mero Traditional Chinese Medicine Factory、Meiluo Pharmaceutical Co., Ltd.、Meiluo Pharmaceutical Company, including 17 subsidiaries and three research institutes，Among them, 9 pharmaceutical subsidiaries account for 9，The main assets are in the Meiro Pharmaceutical Factory、Among the two subsidiaries of the Mero Chinese Pharmaceutical Factory。Another，Mei Luo Pharmaceutical cooperation with Pfizer Pharmaceutical，Established Dalian Pfizer Pharmaceutical Factory，This is the first factory of foreign pharmaceutical companies in China。
Mero Medicine owner's chemical medicine synthesis、Chemical medicine、Chinese patent medicine preparation、Natural health products and other series of products， Forms cardio -cerebral blood vessels、Digestive Internal Medicine、Anti -virus、Anti -tumor、Diabetes、Anti -allergy、Spiritual、Product structure groups in multiple disciplines such as orthopedics。and stake sports betting appits Stake Sports Bettingwounded department of bone slices、Fish ichthyosis tablets、Pearl Popa An Shen Dan and other products are national medicine protection varieties。
With the announcement of the national basic drug catalog，Achicillin from Mero Pharmaceutical、Katopoli、Qiju Dihuang Wan、Xiaoyao Pill (granules)、Qiju Dihuang Wan、Jintui Shenqi Pill (piece)、Angong Niuhuang Wan and other 42 products enter the basic drug catalog。This provides a guarantee for its products to expand sales。
If you get Mero Pharmaceutical，This will greatly enhance the industrial strength of the Sinopharm Group，Another，If successful acquisition，This is also the Chinese Medicine Group will also have another listed company。
But the current Chinese Medicine Holdings only takes Mero Pharmaceutical's commercial network asset，but not won the entire Meiro Pharmaceutical，Explain that there are still obstacles in the acquisition，After all, Mero Pharmaceutical is a listed company。People close to Meiluo Pharmaceutical said，"Where is the specific difference between the Chinese Medicine Group this time?，Not very clear。”
April 24，Mero Pharmaceutical announced，Injecting subordinates' commercial circulation assets and business into Chinese Medicine Holdings Mero (Dalian) Co., Ltd.，Sinopharm Holdings (1099.HK) subsidiaries will have equity cooperation with Sinopharm Holdings Mero and Dalian Meiro Dali Pharmacy Chain Co., Ltd.。
April 26，A person from the Sinopharm Group told reporters，Chinese Medicine Holdings will hold the joint venture，"Acquisition Mero Pharmaceutical Commercial Assets，It is intended to expand the network and sales。”
But the person close to Meiluo Pharmaceutical revealed，"The two parties have been talking for a long time，Sinopharm Group not only wants to acquire Mero Pharmaceutical's commercial assets，More interested in the entire Mero Pharmaceutical。”
Meiluo Pharmaceutical is the main pharmaceutical company in the Northeast，If you get Mero Pharmaceutical，This will enrich the pharmaceutical industry strength of the Chinese Medicine Group，So as to have a bone piece of injury department、Fish ichthyosis tablets、Pearl Po An Shen Dan and other national traditional Chinese medicine protection varieties。
stake sports betting stake online sports bettingappThis newspaper has not been confirmed by the two parties.
stake sports betting appMero Pharmaceutical Announcement Declaration，Mero Pharmaceutical will include the subsidiary Dalian Meiluo Pharmaceutical Company、Dalian Meiro Co., Ltd. New Pharmaceutical Company、Dalian Meiro Pharmaceutical Supply Company、Commercial circulation assets and business, including Dalian Meiruo Chemical Reagent Company, transferred to the wholly -owned subsidiary Sinopharm Holdings Mero (Dalian) Co., Ltd. (referred to as "National Control Mero")
Data display，As of March 31, 2010，Mero Pharmaceutical's transfer of assets transferred assets for total 180 million yuan，Among them, the account receivable is 153 million yuan，Liabilities totaling 142.12 million yuan，Net assets are RMB 38005 million。With the consent of both parties，The total price of the transfer of assets is 380.55 million yuan。
After the asset injection is completed，Meiluo Pharmaceutical will be based on national control Mero，Introduction of domestic pharmaceutical business giants Chinese medicine holding。"Sinopharm Holdings or its designated subsidiaries conduct equity cooperation on the subsidiary Sinopharm Holding Mero Corporation and Dalian Meiro Dali Pharmacy Chain Co., Ltd.。”
It is reported，National Control Mero is a new company set up for this acquisition。
Mero Pharmaceutical did not disclose the acquisition of Chinese medicine holding this time，Is it a wholly -owned acquisition or just hold it。People close to Meiluo Pharmaceutical said，"National Control won the business business of Mero Pharmaceutical this time，The layout of Dalian is also realized。Although the Chinese Medicine Holdings has the national control Shenyang distribution center in the Northeast，But in Dalian，Sinopharm Holdings No cloth。”
The main pharmaceutical assets of Mero Pharmaceuticals are divided into the Industrial Division and the Business Division，People who are close to Mero said，"Mero Pharmaceutical is the main local commercial company in Dalian，annual sales at more than 1 billion yuan。”
For the sale of My stake betting appcommercial assets，Mero Pharmaceutical said，To expand the market share，The need for market competition in the new environment，Being equal and mutually beneficial、Principles of complementary advantages，It is for a long time、Comprehensive strategic partnership，Realize resource sharing、Common development，Meiro and Sinopharm Holdings cooperate with hand。
Back to the Chinese Medicine Holdings，Mero Pharmaceutical hopes to use the Chinese medicine control to control the distribution network of more than 20 provinces and cities across the country，Selling the company's products to the whole country。Agreement in the agreement signed by both parties，42 varieties produced by the pharmaceutical factory of Mero Pharmaceuticals entering the national drug catalog，In the future, the two parties shall be shared by the two parties，Determine about 10 varieties in the directory，Sales of Sinopharm Holdings in its system。
Chinese medicine person said，After winning Mero Pharmaceutical Business，"National Control Shenyang should be integrated with Chinese medicine holding Mero"。
or "one pot" Meiluo Pharmaceutical
But this time the acquisition of Mero Pharmaceutical's commercial assets is not the ultimate purpose of the Sinopharm Group，and its ultimate purpose is to acquire the entire Mero Pharmacy。
The above -mentioned person close to Meiluo Pharmaceutical，"Before the mergers and acquisitions settled，Sinopharm Holdings has always had two versions of the acquisition of Mero Pharmaceutical: one plan is that the Sinopharm Group ‘one pot” all acquires Mero Pharmaceutical; the other plan is to acquire Mero Pharmaceutical business assets。”
"Sinopharm Group really wants to buy Meiro Pharmaceutical this time，And the two parties have been in contact for a long time。"The person said。
2009 financial report display，Mero Pharmaceutical's operating income of 1.337 billion yuan，5.75 % from the previous year; net profit of 1408 million yuan，but a decrease of 64.62 % over the previous year。The decline in net profit is mainly due to stake online sports bettingthe stake online sports bettingcompany's subordinates of the Mero Pharmaceutical Factory and the Mero Chinese Pharmaceutical Factory.。
It is not surprising to acquire Mero Pharmaceuticals to the Chinese Medicine Group，April 23，Sinopharm Group just signed a contract with Shanxi Weichida Company，Chinese Medicine Group Holdings Shanxi Weichida。
Facts，After successful listing，Sinopharm Group with sufficient cash，M & A target is not limited to the business field，and also point the M & A spear head to the pharmaceutical leading enterprise in various regions。
An analyst of a pharmaceutical industry said，After the Chinese Medicine Holdings is listed，The National Medicine Group plans to get 6 billion yuan this year for mergers and acquisitions，Chinese medicine is not just to become the largest business enterprise in China，Also want to be the most influential comprehensive pharmaceutical company。
Meiluo Pharmaceutical is an important pharmaceutical manufacturer in Liaoning，It is the initiator by Mero Group，Substantially launched on July 30, 1999。Listed on the Shanghai Stock Exchange on November 16, 2000。
Meiluo Pharmaceutical now owns the Meiro Pharmaceutical Factory、Mero Traditional Chinese Medicine Factory、Meiluo Pharmaceutical Co., Ltd.、Meiluo Pharmaceutical Company, including 17 subsidiaries and three research institutes，Among them, 9 pharmaceutical subsidiaries account for 9，The main assets are in the Meiro Pharmaceutical Factory、Among the two subsidiaries of the Mero Chinese Pharmaceutical Factory。Another，Mei Luo Pharmaceutical cooperation with Pfizer Pharmaceutical，Established Dalian Pfizer Pharmaceutical Factory，This is the first factory of foreign pharmaceutical companies in China。
Mero Medicine owner's chemical medicine synthesis、Chemical medicine、Chinese patent medicine preparation、Natural health products and other series of products， Forms cardio -cerebral blood vessels、Digestive Internal Medicine、Anti -virus、Anti -tumor、Diabetes、Anti -allergy、Spiritual、Product structure groups in multiple disciplines such as orthopedics。and stake sports betting appits Stake Sports Bettingwounded department of bone slices、Fish ichthyosis tablets、Pearl Popa An Shen Dan and other products are national medicine protection varieties。
With the announcement of the national basic drug catalog，Achicillin from Mero Pharmaceutical、Katopoli、Qiju Dihuang Wan、Xiaoyao Pill (granules)、Qiju Dihuang Wan、Jintui Shenqi Pill (piece)、Angong Niuhuang Wan and other 42 products enter the basic drug catalog。This provides a guarantee for its products to expand sales。
If you get Mero Pharmaceutical，This will greatly enhance the industrial strength of the Sinopharm Group，Another，If successful acquisition，This is also the Chinese Medicine Group will also have another listed company。
But the current Chinese Medicine Holdings only takes Mero Pharmaceutical's commercial network asset，but not won the entire Meiro Pharmaceutical，Explain that there are still obstacles in the acquisition，After all, Mero Pharmaceutical is a listed company。People close to Meiluo Pharmaceutical said，"Where is the specific difference between the Chinese Medicine Group this time?，Not very clear。”
